Sertindole: cardiac electrophysiological profile

REFERENCES

• Haverkamp W, Breithardt G, Camm AJ, et al (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc Res 47: 219–33.
   Google Scholar
• Haverkamp W, Martinez RA, Hief C, et al (1997) Efficacy and safety of d, l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 30: 487 -95.
   PubMedGoogle Scholar
• Hohnloser SH, Singh BN (1995) Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6: 920–36.
   PubMed Web of Science ®Google Scholar
• Roden DM, Thompson KA, Hoffman BF, Woosley RL (1986) Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 8: 73-8A.
   Google Scholar
• Selzer A, Wray HW (1964) Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17–26.
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Hardy S, Archibald D, et al (1996) Sex difference in risk of torsades de pointes with d, l-sotalol. Circulation 94: 2534–41.
   Web of Science ®Google Scholar
• Malik M, Camm AJ (2001) Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Safety 24: 323–51.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Jerry J, Parra F (2002) Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 3: 479–98.
   PubMedGoogle Scholar
• Ponti FD, Poluzzi E, Cavalli A, et al (2002) Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 25: 263–86.
   PubMedGoogle Scholar
• Darpo B (2001) Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J 3 (Suppl:) K70–80.
   Google Scholar
• Rampe D, Murawsky MK, Grau J, Lewis EW (1998) The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286: 788–93.
   PubMed Web of Science ®Google Scholar
• Maginn M, Frederiksen K, Adamantidis MM, et al (2000) The effects of sertindole and its metabolites on cardiac ion channels and action potentials. J Physiol 525P: 79P (Abstract).
   Google Scholar
• Eckardt L, Breithardt G, Haverkamp W (2002) Electrophysio-logic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300: 64–71.
   PubMed Web of Science ®Google Scholar
• Hondeghem LM, Carlsson L, Duker G (2001) Instability and triangulation of the action potential predict serious proar-rhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004–13.
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit (1997) Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96.
   Google Scholar
• Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12 (4): 411–20.
   PubMedGoogle Scholar
• Batchvarov VN, Ghuran A, Smetana P, et al (2002) QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282: H2356–63.
   PubMed Web of Science ®Google Scholar
• Smetana P, Batchvarov VN, Hnatkova K, et al (2002) Sex differences in repolarization homogeneity and its circadian pattern. Am J Physiol Heart Circ Physiol 282 (5): H1889–97.
   Google Scholar
• deBruyne MC, Hoes AW, Kors JA, et al (1999) Prolonged QT interval predicts cardiac and all-cause mortality in the elderly: the Rotterdam study. Eur Heart J 20: 278–84.
   PubMedGoogle Scholar
• Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 301: 427–34.
   PubMed Web of Science ®Google Scholar
• Drici M-D, Wang WX, Liu X-K, et al (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18: 477–81.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou Z, Gong Q, et al (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84: 989–98.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Babuty D, Poret P, et al (1999) Effect of verapamil on QT interval dynamicity. Am J Cardiol 83: 807-8, A10–1.
   Google Scholar
• Benardeau A, Weissenburger J, Hondeghem L, Ertel EA (2000) Effects of the T-type Ca2+ channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue. J Pharmacol Exp Ther 292: 561–75.
   PubMedGoogle Scholar
• Cairns JA, Connolly SJ, Roberts R, et al (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349: 675–82.
   PubMed Web of Science ®Google Scholar
• Julian DG, Camm AJ, Frangin G, et al (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349: 667–74.
   PubMedGoogle Scholar
• van Opstal JM, Schoenmakers M, Verduyn SC, et al (2001) Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104: 2722–7.
   PubMed Web of Science ®Google Scholar
• Ben-David J, Zipes DP (1990) Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarisa-tions and ventricular tachyarrhythmias in dogs. Circulation 82: 225–233.
   PubMedGoogle Scholar
• Lu HR, Marien R, Saels A, De Clerck F (2001) Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated purkinje fibers. J Cardiovasc Electrophysiol 12: 93–102.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Fish J (2001) Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 96: 517–27.
   PubMed Web of Science ®Google Scholar
• Akar FG, Laurita KR, Rosenbaum DS (2000) Cellular basis for dispersion of repolarization underlying reentrant arrhythmias. J Electrocardiol 33 (Suppl:) 23 -31 (Review).
   Google Scholar
• Kozhevnikov DO, Yamamoto K, Robotis D, et al (2002) Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation 105: 1128–34.
   PubMed Web of Science ®Google Scholar
• Yan GX, Wu Y, Liu T, et al (2001) Phase 2 early after-depolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103: 2851–6.
   PubMed Web of Science ®Google Scholar
• Jones DL, Petrie JP, Li HG (2001) Spontaneous, electrically, and cesium chloride induced arrhythmia and afterdepolarizations in the rapidly paced dog heart. Pacing Clin Electrophysiol 24 (4 Pt 1): 474–85.
   Google Scholar
• Adamantidis MM, Dumotier BM, Caron JF, Bordet R (1998) Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol 12: 70–6.
   PubMedGoogle Scholar
• Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA (1996) Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 117: 1377–9.
   PubMedGoogle Scholar
• Adamantidis MM, Lacroix DL, Caron JF, Dupuis BA (1995) Electrophysiological and arrhythmogenic effects of the hista-mine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. J Cardiovasc Pharmacol 26: 319–27.
   PubMedGoogle Scholar
• Gintant GA, Limberis JT, McDermott JS, et al (2001) The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37: 607–1822.
   PubMed Web of Science ®Google Scholar
• de Koning J, van der Hoeven H, Hamer B, Thompson J (1994) Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth J Med 44: 131–5.
   PubMedGoogle Scholar
• Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX (1996) Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 28:
   Google Scholar
• Eckardt L, Haverkamp W, Mertens H, et al (1998) Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d, l-sotalol and erythromycin. J Cardiovasc Pharmacol 32: 425–34.
   PubMed Web of Science ®Google Scholar